Understand the source comparison
Selank Amidate Anxiety Reduction Results Timeline Expect: Comparison
20–40 minutes (Acute Onset) Enkephalin degradation inhibition; acute GABAergic tone modulation Subjective calming; reduced autonomic arousal (lower heart rate, reduced muscle tension) Acute phase provides immediate relief but is not the therapeutic endpoint. U
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 20–40 minutes (Acute Onset)
- Enkephalin degradation inhibition; acute GABAergic tone modulation
- Subjective calming; reduced autonomic arousal (lower heart rate, reduced muscle tension)
- Acute phase provides immediate relief but is not the therapeutic endpoint. Users must continue to the neuroplastic phase
- 3–4 hours (Peak Concentration)
- Peak plasma Selank; maximum monoamine oxidase modulation
- Peak anxiolytic effect; most pronounced reduction in stress reactivity
- Peak pharmacological response. Not sustainable long-term without neuroplastic changes
- Days 1–7 (Normalisation Phase)
- Sustained monoamine metabolism regulation; cortisol response dampening
- Improved stress resilience; reduced ruminative thought loops
- Preparatory phase for BDNF upregulation. Users who stop here miss the long-term benefit
- Days 7–21 (Neuroplastic Phase)
- BDNF upregulation; TrkB receptor activation; dendritic spine proliferation
- Sustained baseline anxiety reduction; improved fear-extinction learning
- This is the therapeutic window. Structural changes persist weeks after discontinuation
- Post-Day 21 (Sustained Benefit)
- Maintained synaptic density in hippocampus and prefrontal cortex
- Anxiety reduction persists without daily dosing
- Evidence of genuine neuroplastic adaptation rather than acute pharmacological dependence